Lapatinib is frequently used in combination with other therapeutic agents for treating high-risk metastatic breast cancer patients, particularly in cases where they display resistance to trastuzumab, a first-line therapeutic agent for HER2-positive breast cancer [3, 4]. This evidence concerns the gene ERBB2 and breast carcinoma.